Yuki Takeyasu
About
Yuki Takeyasu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Physiology.
According to data from OpenAlex, Yuki Takeyasu has authored 29 papers receiving a total of 242 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 5 papers in Physiology. Recurrent topics in Yuki Takeyasu's work include Lung Cancer Treatments and Mutations (17 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Lung Cancer Research Studies (9 papers). Yuki Takeyasu is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Lung Cancer Research Studies (9 papers). Yuki Takeyasu collaborates with scholars based in Japan, United Kingdom and United States. Yuki Takeyasu's co-authors include Takayasu Kurata, Makoto Ogata, Maiko Niki, Shosaku� Nomura, Kayoko Kibata, Takayuki Miyara, Aya Nakaya, Hiroshige Yoshioka, Yuji Matsumoto and Noboru Yamamoto and has published in prestigious journals such as SHILAP Revista de lepidopterología, Annals of Oncology and BMC Cancer.
In The Last Decade
Yuki Takeyasu
26 papers receiving 239 citations
Peers
Yuki Takeyasu
Silvana Acquafredda Italy
Ina Valeria Zurlo Italy
Ying Cheng China
David Vicente Baz Spain
Andreas Jakob Germany
Rui Kitadai Japan
T-E. Ciuleanu Romania
Rocco Giannicola Italy
Şeyda Gündüz Türkiye
Krassimir Koynov Bulgaria
Citations per year, relative to Yuki Takeyasu Yuki Takeyasu (= 1×)
peers
Silvana Acquafredda
Countries citing papers authored by Yuki Takeyasu
Since
Specialization
Citations
This map shows the geographic impact of Yuki Takeyasu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuki Takeyasu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuki Takeyasu more than expected).
Fields of papers citing papers by Yuki Takeyasu
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Yuki Takeyasu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuki Takeyasu. The network helps show where Yuki Takeyasu may publish in the future.
Co-authorship network of co-authors of Yuki Takeyasu
This figure shows the co-authorship network connecting the top 25 collaborators of Yuki Takeyasu. A scholar is included among the top collaborators of Yuki Takeyasu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuki Takeyasu. Yuki Takeyasu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Shirasawa, Masayuki, Tatsuya Yoshida, Takaji Matsutani, et al.. (2025). Diversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLC. npj Precision Oncology. 9(1). 17–17.
2.
Ota, Takayo, Yuki Takeyasu, Satoaki Nakamura, et al.. (2024). Feasibility Study of Nivolumab in Combination with Carboplatin Plus Paclitaxel and Concurrent Thoracic Radiation in Patients with Untreated Unresectable Locally Advanced Non-Small Cell Lung Cancer. Cancers. 16(18). 3127–3127.
3.
Takeyasu, Yuki, Tsutomu Yoshida, Akio Tateishi, et al.. (2024). Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC. SHILAP Revista de lepidopterología. 5. 100058–100058.
4.
Fukushima, Takuya, Jiro Nakano, Kazuki Fujii, et al.. (2024). Comparative Study on Associations Between Lung Cancer Prognosis and Diagnostic Criteria Set by the European Palliative Care Research Collaboration and the Asian Working Group for Cachexia. Thoracic Cancer. 16(2). e15503–e15503.
5.
Yagishita, Shigehiro, Yoshiharu Hayashi, Yuki Takeyasu, et al.. (2023). Impact of ramucirumab pharmacokinetics in combination with docetaxel on the efficacy and survival in patients with advanced non-small cell lung cancer. Lung Cancer. 178. 247–253.
6.
Yoshida, Tatsuya, Yuki Takeyasu, Yuji Matsumoto, et al.. (2023). Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non‐small cell lung cancer patients. Cancer Medicine. 12(11). 12388–12401.
7.
Ikeda, Y., et al.. (2023). A Case of Radiation Recall Pneumonitis Caused by Nivolumab+Ipilimumab Combination Therapy. Haigan. 63(4). 319–324.
8.
Nakamura, Tomoaki, Tatsuya Yoshida, Yuki Takeyasu, et al.. (2023). Distinct metastatic spread and progression patterns in patients treated with crizotinib for ROS1- and ALK-rearranged non-small cell lung cancer: a single-center retrospective study. Translational Lung Cancer Research. 12(7). 1436–1444.
9.
Tanaka, Tomohiro, Tatsuya Yoshida, Ken Masuda, et al.. (2022). Prognostic role of modified Glasgow Prognostic score in elderly non-small cell lung cancer patients treated with anti-PD-1 antibodies. Respiratory Investigation. 61(1). 74–81.
10.
Nakamura, Tomoaki, Yuki Takeyasu, Tatsuya Yoshida, Ken Ohashi, & Yuichiro Ohe. (2022). End‐of‐life impact of concurrent diabetes mellitus and adrenal insufficiency as immune‐related adverse events in an advanced non‐small cell lung cancer patient. Thoracic Cancer. 13(21). 3073–3075.
11.
Takeyasu, Yuki, Tatsuya Yoshida, Ken Masuda, et al.. (2022). Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib. JTO Clinical and Research Reports. 3(5). 100311–100311.
12.
Takeyasu, Yuki, Hitomi Sumiyoshi Okuma, Yuki Kojima, et al.. (2021). Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors. JCO Precision Oncology. 5(5). 756–766.
13.
Imabayashi, Tatsuya, Yuki Takeyasu, Midori Tanaka, et al.. (2021). The Impact of Core Tissues on Successful Next-Generation Sequencing Analysis of Specimens Obtained through Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration. Cancers. 13(23). 5879–5879.
14.
Takeyasu, Yuki, Tatsuya Yoshida, Ryota Shibaki, et al.. (2020). Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC. Clinical Lung Cancer. 22(2). 127–133.e3.
15.
Saito, Tomohito, Koji Tsuta, Mitsuaki Ishida, et al.. (2018). Comparative study of programmed cell death ligand-1 immunohistochemistry assays using 22C3 and 28-8 antibodies for non-small cell lung cancer: Analysis of 420 surgical specimens from Japanese patients. Lung Cancer. 125. 230–237.
16.
Takeyasu, Yuki, Yasushi Goto, Ryo Morita, et al.. (2018). Efficacy and safety of epidermal growth factor receptor (EGFR) - Tyrosine kinase inhibitors (TKI) in elderly patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). Annals of Oncology. 29. ix160–ix161.
17.
Takeyasu, Yuki, Atsushi� Satake, Hideaki� Yoshimura, et al.. (2017). Tyrosine kinase inhibitor and rituximab‐ CHOP treatment for concurrent chronic myeloid leukemia and non‐Hodgkin lymphoma: a case report. Clinical Case Reports. 5(12). 2047–2050.
18.
Saito, Tomohito, Koji Tsuta, Yuki Takeyasu, et al.. (2017). Comparison Study of PD-L1 Immunohistochemistry Assays with 22C3 and 28-8: Analysis on 147 Surgically Resected NSCLC. Annals of Oncology. 28. ix84–ix84.
19.
Nakatani, Yuki, Aya Nakaya, Takayasu Kurata, et al.. (2017). Interstitial Lung Disease Following Single-Agent Nanoparticle Albumin-Bound Paclitaxel Treatment in Patients with Advanced Non-Small Cell Lung Cancer. Case Reports in Oncology. 10(2). 683–688.
20.
Nakaya, Aya, Takayasu Kurata, Takashi Yokoi, et al.. (2017). Retrospective analysis of single-agent nab-paclitaxel in patients with platinum-resistant non-small cell lung cancer. Molecular and Clinical Oncology. 7(5). 803–807.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Silvana Acquafredda Breakdown of academic impact, for papers by Ina Valeria Zurlo Breakdown of academic impact, for papers by Ying Cheng Breakdown of academic impact, for papers by David Vicente Baz Breakdown of academic impact, for papers by Andreas Jakob Breakdown of academic impact, for papers by Rui Kitadai Breakdown of academic impact, for papers by T-E. Ciuleanu Breakdown of academic impact, for papers by Rocco Giannicola Breakdown of academic impact, for papers by Şeyda Gündüz Breakdown of academic impact, for papers by Krassimir Koynov